Nanostrategies to Develop Current Antiviral Vaccines

ACS Appl Bio Mater. 2021 May 17;4(5):3880-3890. doi: 10.1021/acsabm.0c01284. Epub 2021 Apr 27.

Abstract

Infectious diseases are a worldwide concern. They are responsible for increasing the mortality rate and causing economic and social problems. Viral epidemics and pandemics, such as the COVID-19 pandemic, force the scientific community to consider molecules with antiviral activity. A number of viral infections still do not have a vaccine or efficient treatment and it is imperative to search for vaccines to control these infections. In this context, nanotechnology in association with the design of vaccines has presented an option for virus control. Nanovaccines have displayed an impressive immune response using a low dosage. This review aims to describe the advances and update the data in studies using nanovaccines and their immunomodulatory effect against human viruses.

Keywords: SARS-CoV-2; immune system; nanotechnology; nanovaccines; peptide-based vaccines; viral infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adaptive Immunity
  • COVID-19 Vaccines
  • Humans
  • Immunity, Innate
  • Nanomedicine / trends*
  • Vaccine Development / trends*
  • Vaccines, DNA
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • Viral Vaccines* / immunology
  • Virus Diseases / prevention & control*
  • mRNA Vaccines

Substances

  • COVID-19 Vaccines
  • Vaccines, DNA
  • Vaccines, Subunit
  • Vaccines, Synthetic
  • Viral Vaccines
  • mRNA Vaccines